Search

Your search keyword '"G.G. Di Costanzo"' showing total 58 results
Start Over Author "G.G. Di Costanzo" Topic hepatology
58 results on '"G.G. Di Costanzo"'

2. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study

Author

M. Rendina, M. Barone, S. Trapani, L. Masiero, P. Trerotoli, F. Puoti, L.G. Lupo, S. Agnes, A. Grieco, E. Andorno, S. Marenco, U. Baccarani, P. Toniutto, A. Carraro, A. Colecchia, M. Cescon, M.C. Morelli, U. Cillo, P. Burra, P. Angeli, M. Colledan, S. Fagiuoli, L. De Carlis, L. Belli, P. De Simone, P. Carrai, F. Di Benedetto, N. De Maria, G.M. Ettorre, V. Giannelli, S. Gruttadauria, R. Volpes, V. Mazzaferro, S. Bhoori, R. Romagnoli, S. Martini, G. Rossi, F. Donato, M. Rossi, S. Ginanni Corradini, M. Spada, G. Maggiore, G. Tisone, I. Lenci, G. Vennarecci, G.G. Di Costanzo, M. Vivarelli, G. Svegliati Baroni, F. o Zamboni, L. Mameli, S. Tafuri, S. Simone, L. Gesualdo, M. Cardillo, and A. Di Leo

Subjects
Hepatology, Gastroenterology
Published
2022

3. Psychological profiles and risk of relapse in cirrhosis due to alcohol abuse

Author

D. Ferraro, I. Esposito, Antonio Ceriello, D. Pisaniello, A. Cangiano, F. Giordano, Carla Migliaccio, F.P. Picciotto, G.G. Di Costanzo, V.G.M. Moreas, G. Arenga, G. Aragiusto, A. Galeota Lanza, G. Mazzarone, C. Chierego, Ciro Esposito, L. Campanella, and Giovanni Vennarecci

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, Alcohol abuse, Relapse risk, business, medicine.disease
Published
2021

4. AF.93 COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIAN CASE-CONTROL DOUBLE-CENTER STUDY

Author

Michele Pier Luca Guarino, M. Capasso, V. Cozza, L. De Coppi, Valentina Cossiga, Ilaria Loperto, F.P. Picciotto, R. Ortolani, I. Esposito, Giuseppina Pontillo, Andrea Fiorentino, Filomena Morisco, G.G. Di Costanzo, and L. Pignata

Subjects
2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, Hepatology, Coronavirus disease 2019 (COVID-19), Liver, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, medicine, Center (algebra and category theory), business, Abstracts of the 27th National Congress of Digestive Diseases 2021 – FISMAD
Published
2021

5. Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model

Author

Rodolfo Sacco, T. Pressiani, Alessandro Granito, R. Tortora, G.G. Di Costanzo, Franco Trevisani, Vito Sansone, Francesco Tovoli, Luca Ielasi, Andrea Casadei-Gardini, and Giulia Magini

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, External validation, business, medicine.disease, medicine.drug
Published
2020

6. Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study

Author

Salvatore Gruttadauria, Marco Vivarelli, Fausto Zamboni, S. Ginanni Corradini, L. Lupo, Silvia Martini, L. De Carlis, Stefano Fagiuoli, Ilaria Lenci, Giuseppe Valerio Bianco, Lino Belli, P De Simone, W. Santaniello, Gabriele Spoletini, Pierluigi Toniutto, Renato Romagnoli, L. Mameli, Matteo Cescon, Valerio Giannelli, Michele Colledan, A.W. Avolio, Antonio Benedetti, Quirino Lai, Riccardo Volpes, G.G. Di Costanzo, Giuseppe Maria Ettorre, U Tedeschi, G. Tisone, A. Grieco, Amedeo Carraro, Sherrie Bhoori, Salvatore Agnes, Paola Carrai, Francesco Donato, U. Cillo, P. Burra, A Franco, Andrea Risaliti, Gemma Rossi, V. Nobile, F. Di Benedetto, C. Donato, R. Calia, Marcos A. Rossi, M. Rendina, Marco Spada, Vincenzo Mazzaferro, N. De Maria, Avolio, A, Lai, Q, Franco, A, Bianco, G, Calia, R, Spoletini, G, Agnes, S, Grieco, A, Rossi, M, Corradini, S, Vivarelli, M, Benedetti, A, Lupo, L, Rendina, M, Colledan, M, Fagiuoli, S, Cescon, M, Donato, C, Zamboni, F, Mameli, L, De Carlis, L, Belli, L, Rossi, G, Donato, F, Mazzaferro, V, Bhoori, S, Di Benedetto, F, De Maria, N, Santaniello, W, Di Costanzo, G, Gruttadauria, S, Volpes, R, De Simone, P, Carrai, P, Spada, M, Nobile, V, Ettorre, G, Giannelli, V, Tisone, G, Lenci, I, Romagnoli, R, Martini, S, Risaliti, A, Toniutto, P, Tedeschi, U, Carraro, A, Burra, P, and Cillo, U

Subjects
Pediatrics, medicine.medical_specialty, Case mix index, Hepatology, liver transplantation, business.industry, medicine.medical_treatment, Gastroenterology, medicine, Patient survival, Liver transplantation, business
Published
2019

7. Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation

Author

M. Romero Cristóbal, Marcus-Alexander Wörns, R. Prince, L. Scuddeler, G. Sapisochin, M.L. González-Diéguez, Claudio Zavaglia, Helene Regnault, Maria Margarita Anders, Federica Invernizzi, Jordi Bruix, Giuliana Amaddeo, Lucia Cesarini, M. Reig, Álvaro Díaz-González, Matteo Angelo Manini, Matthias Pinter, Marco Sanduzzi-Zamparelli, M. Fraile-López, R. Tortora, Tommy Ivanics, Stefano Mazza, P. Daechul Yoon, Maria Francesca Donato, M.J. Blanco Rodríguez, Vincenzo Mazzaferro, Federico Piñero, M. Varela, Carolin Czauderna, Gonzalo Crespo, A. Fernandez Yunquera, Gerda Elisabeth Villadsen, Massimo Iavarone, G. Aballay Soteras, M. De Giorgio, Pietro Lampertico, G.G. Di Costanzo, Sherrie Bhoori, and Arndt Weinmann

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Liver transplantation, chemistry.chemical_compound, chemistry, Regorafenib, Internal medicine, medicine, In patient, business, medicine.drug
Published
2021

9. P.04.14 HEPATOCELLULAR CARCINOMA AND SMOKING ARE INDEPENDENT RISK FACTORS FOR DEVELOPMENT OF DE-NOVO EXTRAHEPATIC TUMORS IN LIVER TRANSPLANT RECIPIENTS

Author

Luigi Addario, M. De Luca, A. Telese, A. Galeota Lanza, M.T. Tartaglione, F. Lampasi, W. Santaniello, Luigi Gaeta, G.G. Di Costanzo, F.P. Picciotto, G. Cordone, and R. Tortora

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, business, medicine.disease
Published
2019

10. OC.07.4 HCC RECURRENCE AFTER DAA TREATMENT IN HCV PATIENTS

Author

Federica Morando, Nicola Coppola, Filomena Morisco, Luca Rinaldi, Michele Pier Luca Guarino, Marco Guarracino, A. Salomone Megna, Nicola Caporaso, G.G. Di Costanzo, Marcello Persico, Dario Bruzzese, and Anna Sessa

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published
2019

12. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma

Author

M. Scartozzi, G. Cordone, Vincenzo Palmieri, Luca Faloppi, R. Tortora, G. Ercoloani, G.G. Di Costanzo, N. Silvestris, Stefano Cascinu, Giorgia Marisi, Francesco Giuseppe Foschi, R. Granata, A. Casadei Gardini, and Oronzo Brunetti

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Scoring system, Hepatology, business.industry, Gastroenterology, medicine.disease, Simple (abstract algebra), Hepatocellular carcinoma, Internal medicine, medicine, In patient, business, medicine.drug
Published
2017

13. HCC recurrence after DAA treatment in HCV patients

Author

Nicola Coppola, Filomena Morisco, Nicola Caporaso, Luca Rinaldi, Federica Morando, G.G. Di Costanzo, A. Salomone Megna, Michele Pier Luca Guarino, Marco Guarracino, Marcello Persico, and Dario Bruzzese

Subjects
03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, 030211 gastroenterology & hepatology, business, 030226 pharmacology & pharmacy
Published
2018

14. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: A pilot study

Author

Charlotte K.Y. Ng, Cristina Quintavalle, Markus H. Heim, Stefan Wieland, Matthias S. Matter, Salvatore Piscuoglio, G. Marino-Marsilia, Giuseppina Roscigno, R. Tortora, Viola Paradiso, Marco Guarracino, Manuela Lanzafame, T. Boldanova, Mairene Coto-Llerena, Luca Quagliata, Valeria Perrina, G.G. Di Costanzo, Nadia Tosti, Gerolama Condorelli, and L. Terracciano

Subjects
0301 basic medicine, Hepatology, business.industry, Plasma derived, Gastroenterology, medicine.disease, Therapy naive, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, DNA profiling, Cell-free fetal DNA, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Cancer research, medicine, business
Published
2018

15. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC)

Author

P. Giovanis, S. D'Angelo, Mario Pirisi, G. de Stefano, Adolfo Francesco Attili, D. Sansonno, Antonio Benedetti, T. Zolfino, Salvatore Pisconti, Giuseppe Cabibbo, Lydia Giannitrapani, Bruno Daniele, Vito Lorusso, M. Moscovici, Rodolfo Sacco, Vincenzo Montesarchio, P. Carucci, G.G. Di Costanzo, F. De Vita, and Angela Buonadonna

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Clinical Practice, Pooled analysis, Hepatocellular carcinoma, Internal medicine, medicine, Observational study, business, medicine.drug
Published
2016

16. P.09.7: Mucosal GUT Microbiota Composition in Patients with HCV Infection, from Chronic Hepatitis to Hepatocellular Carcinoma

Author

Pietro Coccoli, V. Precone, Domenica Lovero, V. D’Argenio, G.G. Di Costanzo, S. Saviano, Alice Di Rocco, Gerardo Nardone, Debora Compare, Graziano Pesole, M. Sanduzzi Zamparelli, Mauro Esposito, G. Casaburi, Bruno Fosso, I. Postiglione, and Francesco Salvatore

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Gut flora, medicine.disease, biology.organism_classification, Chronic hepatitis, Internal medicine, Hepatocellular carcinoma, Medicine, In patient, business
Published
2017

18. Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience

Author

Michele Pier Luca Guarino, R. Tortora, G. Cordone, M.S. Zamparelli, G.G. Di Costanzo, and R. Granata

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Single Center, Gastroenterology, Virology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Hepatocellular carcinoma, medicine, 030211 gastroenterology & hepatology, business
Published
2017

20. Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania

Author

Le Adinolfi, G. de Stefano, G. Nardone, G. Francica, Guido Piai, Francesco Izzo, Giuseppe D'Adamo, S.M. Angelo, Carmine Coppola, Michele Pier Luca Guarino, V. De Girolamo, G.B. Gaeta, Nicola Coppola, Vincenzo Messina, R. Tortora, G.G. Di Costanzo, and Filomena Morisco

Subjects
medicine.medical_specialty, Hepatology, Field practice, business.industry, Family medicine, Medicine, business
Published
2016

23. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy

Author

Carmine Coppola, Filomena Morisco, S. Camera, G.G. Di Costanzo, Alessandro Federico, Ernesto Claar, Davide F Precone, Marcello Persico, A. De Luna, A. Salomone Megna, Mario Masarone, R. Granata, Nicola Coppola, Valerio Rosato, and Ivan Gentile

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine, business, Intensive care medicine, Real life data, Telaprevir, medicine.drug
Published
2014

24. P.17.10 ADHERENCE TO TRIPLE THERAPY IN HCV

Author

Nicola Caporaso, Michele Pier Luca Guarino, S. Camera, G.G. Di Costanzo, F. Lampasi, R. Granata, Valentina Cossiga, M.T. Tartaglione, Ilaria Loperto, Filomena Morisco, C. Ferraiuoli, and E. Clery

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, business
Published
2014

25. P0369 : Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients

Author

Concetta Tuccillo, R. Granata, Francesco Auriemma, Nicola Caporaso, Filomena Morisco, G.G. Di Costanzo, Ilaria Loperto, Andrea Gallotta, Maria Guarino, R. Tortora, and Giorgio Fassina

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.disease, Lower risk, Gastroenterology, MERTK Gene, Liver disease, Internal medicine, Genotype, medicine, Biomarker (medicine), SNP, business
Abstract

s / Digestive and Liver Disease 46S (2014) e136–e141 e137 all 248 patients had reached HBV undetectability

Published
2015

26. P.18.23 SCCA-IgM: A BIOMARKER TO MONITOR THE OUTCOME OF THERAPY WITH SORAFENIB IN ADVANCED HCC

Author

Nicola Caporaso, Francesco Auriemma, R. Tortora, Michele Pier Luca Guarino, C. Ferraiuoli, Ilaria Loperto, L. Beneduce, Concetta Tuccillo, Filomena Morisco, and G.G. Di Costanzo

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Biomarker (medicine), business, medicine.drug
Published
2013

27. 524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS

Author

G.G. Di Costanzo, A. Caputo, María Isabel Colombo, Mauro Viganò, Tiziana Giuberti, Patrizia Farci, Fabio Facchetti, Silvia Fargion, Evangelista Sagnelli, Pietro Lampertico, Loredana Regep, S. Boninsegna, Massimo Fasano, Vivien Rothe, and V. Di Marco

Subjects
medicine.medical_specialty, HBsAg, Hepatology, Hbeag negative, business.industry, Internal medicine, Genotype, medicine, business, Gastroenterology, Peginterferon alfa-2a, medicine.drug
Published
2012

28. F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance

Author

G.G. Di Costanzo, T. Santantonio, Evangelista Sagnelli, S. Pierconti, Giuseppe Mazzella, Vincenzo Messina, Pietro Lampertico, Mario Angelico, L. Cimino, Gianluca Brancaccio, Grazia Anna Niro, G. Raimondo, G.B. Gaeta, Stefano Fagiuoli, Mauro Viganò, M. Puoti, Massimo Levrero, Miroslava Subic, Angelo V. Marzano, V. Di Marco, and C. Sava

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Internal medicine, Gastroenterology, medicine, Prospective cohort study, business, medicine.drug
Published
2011

36. 194 ANTI-HBV IMMUNOPROPHYLAXIS IN LIVER TRANSPLANTED PATIENTS USING SUBCUTANEOUS ADMINISTRATION OF HBIG: PRELIMINARY RESULTS OF AN ONGOING OBSERVATIONAL STUDY

Author

Carla Migliaccio, A. Galeota Lanza, F. Calise, Michele Imparato, G.G. Di Costanzo, M. Romano, Antonio Giuliani, F.P. Picciotto, and Giuseppe Surfaro

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, Observational study, Intensive care medicine, business, Administration (government), Anti hbv
Published
2012

37. P.08.2 SERUM LEVELS OF SCCA-IGM ARE RELATED TO THE EFFICACY OF HCC TREATMENTS

Author

Filomena Morisco, A. Mariniello, G.G. Di Costanzo, R. Tortora, Nicola Caporaso, S. Camera, Concetta Tuccillo, Ilaria Loperto, L. Beneduce, Michele Pier Luca Guarino, and L. Donnarumma

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business
Published
2012

40. P.1.97: SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA: EFFECTIVENESS AND IMPACT OF ADVERSE EFFECTS IN DAILY CLINICAL PRACTICE

Author

M. De Luca, A. Galeota Lanza, G.G. Di Costanzo, R. Pacilio, R. Tortora, M.T. Tartaglione, and F. Lampasi

Subjects
Oncology, medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Colorectal cancer, business.industry, Incidence (epidemiology), Gastroenterology, Colonoscopy, Context (language use), medicine.disease, Quality of life, Internal medicine, medicine, Economic impact analysis, Activity-based costing, Adverse effect, business, Intensive care medicine
Abstract

Background and aim: Colorectal cancer (CRC) represents the second leading cause of cancer mortality in Europe. Evidence from several scientific studies suggests that screening for the early detection and removal of cancerous lesions can reduce its incidence and mortality and improve patients’ quality of life. The main literature on this topic refers to the American context, which is extremely different from the Italian one. The aim is to propose the results of a cost-effectiveness analysis of a screening program in Italy using as case-study the experience of a CRC screening program started in 2005 in the Province of Ferrara, to determine the full cost of the screening program and to compare the costs-effectiveness of FOBT and colonoscopy. Material and methods: A micro-costing analysis is used to identify and evaluate all the costs involved in each phase of the screening program, following an activity-based costing approach to consider all the activities carried out in the assistance process. The effectiveness of the diagnostic instrument used, FOBT combined with colonoscopy, is valued in terms of early detected lesions and years of life gained. Finally, we use the cost and effectiveness data collected to estimate the costs for year of life gained using a MISCAN-COLON Model. Results: The preliminary results show that, after the screening implementation, a huge number of new cases of hyperplasic polyps, dysplastic adenomas and carcinomas are detected. Moreover, early diagnosis allows the diagnosis of colorectal cancer at the earliest Dukes’ stages. The results of the Model show that the screening program will reduce mortality of 11% and prevent almost 1,100 deaths, with 12,741 years of life gained in a period of time of 30 years. Comparing the costs born in the first wave of the screening with the number of years potentially saved, the model shows that the incremental cost-effectiveness ratio of the program is almost €5,315 for life year. Conclusions: This study shows the economic benefits of the screening program estimated in similar studies conducted in other countries (Sonnenberg, 2000). Besides, the paper highlights the importance of implementing a screening program not only for the effects that prevention can have in clinical terms, but also for the economic impact of such a policy in terms of long-term sustainability of healthcare systems.

Published
2011

41. 732 EFFICACY AND TOLERANCE OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER PROSPECTIVE OPEN LABEL STUDY

Author

G.G. Di Costanzo, G. Raimondo, Mauro Viganò, Evangelista Sagnelli, Giuseppe Mazzella, Miroslava Subic, Grazia Anna Niro, T. Santantonio, Pietro Lampertico, G.B. Gaeta, F. Stefano, Giuseppina Brancaccio, V. Di Marco, Vincenzo Messina, Barbara Testoni, Alfredo Marzano, C. Sava, Massimo Levrero, M. Puoti, Mario Angelico, and L. Cimino

Subjects
medicine.medical_specialty, HBsAg, Hepatology, Tenofovir, business.industry, Urinary system, Renal function, Pharmacology, Gastroenterology, Open label study, Internal medicine, Toxicity, medicine, Dosing, Adverse effect, business, medicine.drug
Abstract

but 28% had reduced urinary phosphate absorption, as assessed by estimated TmPI/GFR, Overall, TDF dosing was reduced or discontinued in 3.3% of the patients because of renal toxicity or other adverse events. Two patients cleared HBsAg and discontinued TDF successfully. Conclusions: TDF suppressed HBV replication in most NUC-naive patients in field practice up to 21 months with few patients showing an impairment of renal function.

Published
2011

42. 414 PEG-INTERFERON PLUS RIBAVIRIN TREATMENT DOES NOT IMPROVE RECURRENCE AFTER RESECTION OR ABLATION OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS: A CASE-CONTROL STUDY

Author

A. Galeota Lanza, M. De Luca, G.G. Di Costanzo, M.T. Tartaglione, F. Lampasi, and R. Tortora

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, Case-control study, Ablation, medicine.disease, Gastroenterology, Resection, Peg interferon, chemistry.chemical_compound, chemistry, Hepatocellular carcinoma, Internal medicine, medicine, business
Published
2011

43. P.1.1: PREDICTIVE FACTORS FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB

Author

M. De Luca, R. Pacilio, A. Galeota Lanza, F. Lampasi, R. Tortora, M.T. Tartaglione, and G.G. Di Costanzo

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Univariate analysis, Hepatology, business.industry, Gastroenterology, medicine.disease, Rash, Portal vein thrombosis, Metastasis, Internal medicine, Hepatocellular carcinoma, Ascites, medicine, medicine.symptom, Varices, business, medicine.drug
Abstract

Background and aim: Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the predictive factors of outcome among treated patients have not been fully investigated. Aim of this study was to identify factors predictive for tumor control among patients with advanced HCC treated with sorafenib. Material and methods: All consecutive HCC patients treated with sorafenib at our Unit from October 2008 to October 2010 were evaluated. All patients received 800 mg/day of sorafenib until progression or unacceptable toxicities. Overall survival (OS) and time to progression (TTP) were estimated by using Kaplan-Meier curves. TTP was considered as a marker of tumor control. Univariate analysis included age, gender, etiology, AFP, Child-Pugh class, MELD, alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, albumin, ascites, metastasis, portal vein thrombosis, oesophageal varices, effects related to VEGF inhibition: rash, arterial hypertension, bleeding, and hand-foot syndrome (HFS). To detect factors independently related to TTP, multivariate analysis by Cox’s model was done. Results: We treated 101 patients (median age 67 years; 81 males; 98 cirrhotics; Child A/B: 79/19; 55 macrovascular invasion; 39 extrahepatic spread). Median therapy duration was 4 (range 1-16) months. Median OS was 10 (95% CI 4.5-15.5) months. TTP was 9 (95%CI 3.7-14.3) months. Complete/partial response occurred in 21% of patients and stable disease in 19%. At univariate analysis, the variables significantly related to TTP were: female sex (14 months vs 6 months, p=.05), no portal thrombosis (13 months vs 6 months, p=.04), ALT =60UI (15 months vs 6 months, p=.02), no ascites (11 months vs 2 months, p=.003), and occurrence of HFS (16 months vs 5 months, p

Published
2011

44. OC.10.1: RADIOFREQUENCY ABLATION VERSUS LASER ABLATION FOR THE TREATMENT OF SMALL HEPATOCELLULAR CARCINOMA: A RANDOMIZED CONTROLLED TRIAL

Author

N. Carannante, G.G. Di Costanzo, F. Lampasi, A. Galeota Lanza, Giuseppe D'Adamo, Claudio Maurizio Pacella, R. Tortora, M.T. Tartaglione, and M. De Luca

Subjects
Laser ablation, Hepatology, Randomized controlled trial, business.industry, law, Radiofrequency ablation, Hepatocellular carcinoma, Gastroenterology, medicine, medicine.disease, Nuclear medicine, business, law.invention
Published
2011

48. Is daily dose of IFN plus ribavirin more effective than standard IFN plus ribavirin regimen for HCV related liver disease? A prospective randomized study

Author

Wanda Utech, F.P. Picciotto, F. Lampasi, M. De Luca, Antonio Ascione, G.G. Di Costanzo, and C. Canestrini

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.disease, Gastroenterology, Virology, Liver disease, Regimen, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Prospective randomized study, business
Published
2001

49. 98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B

Author

María Isabel Colombo, G.G. Di Costanzo, P. Fedeli, Massimo Fasano, C. Iannacone, Patrizia Farci, V. Di Marco, Silvia Fargion, S. Boninsegna, Tiziana Giuberti, Benedetta Massetto, Mauro Viganò, Evangelista Sagnelli, and Pietro Lampertico

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, Hbeag negative, business.industry, Sustained response, Internal medicine, Genotype, medicine, business, Gastroenterology, Peginterferon alfa-2a, medicine.drug
Published
2010

50. 1010 OPTIB – A MULTICENTER PROSPECTIVE OPEN LABEL STUDY ON TENOFOVIR (TDF) FOR CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADV OR ADV/LAM TREATMENT

Author

S. Pierconti, Giuseppina Brancaccio, G.G. Di Costanzo, G.B. Gaeta, Grazia Anna Niro, Stefano Fagiuoli, T. Santantonio, Massimo Levrero, V. Di Marco, Vincenzo Messina, Giuseppe Mazzella, Evangelista Sagnelli, Mario Angelico, L. Cimino, C. Sava, Pietro Lampertico, G. Raimondo, Mauro Viganò, and Angelo V. Marzano

Subjects
medicine.medical_specialty, Hepatology, Open label study, Chronic hepatitis, Tenofovir, business.industry, Internal medicine, medicine, business, Gastroenterology, Surgery, medicine.drug
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results